Potential application of the bulk RNA sequencing in routine MPN clinics

Area of Science:

• Hematology
• Oncology
• Genomics

Background:

• Myeloproliferative neoplasms (MPNs) are chronic hematological malignancies with complex genetic mutations and immune dysregulation.
• Understanding the genetic and immune landscape is vital for effective MPN treatment.
• Advanced techniques are costly; bulk RNA sequencing (RNA-Seq) offers a viable alternative.

Purpose of the Study:

• To evaluate the utility of bulk RNA sequencing (RNA-Seq) for analyzing gene mutations and immune profiles in MPNs.
• To explore RNA-Seq as a cost-effective tool for MPN research and clinical application.

Main Methods:

• RNA sequencing was performed on peripheral blood and bone marrow samples from treatment-naïve patients with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
• Publicly available microarray datasets (GSE26049, GSE2191) were integrated into the analysis.
• Bioinformatics approaches were utilized to interpret genetic mutations and immune landscapes.

Main Results:

• RNA-Seq successfully identified gene mutations relevant to MPN development.
• The study characterized the immune profile, including immune cell infiltration and cytokine patterns.
• Distinct immune-related pathways implicated in MPN pathogenesis were elucidated.

Conclusions:

• Bulk RNA-Seq is a practical and feasible tool for routine clinical use in managing MPNs.
• This approach provides comprehensive insights into the immune and genetic characteristics of MPNs.
• RNA-Seq can enhance personalized treatment strategies and improve prognostic accuracy for MPN patients.